Clinical Trials Logo

Clinical Trial Summary

This phase II trial compares the effect of rectus sheath block with liposomal bupivacaine to thoracic epidural analgesia (TEA) on pain control in patients following surgical removal of all or part of the pancreas and duodenectomy (pancreatoduodenectomy). Administering long acting local anesthetics, such as liposomal bupivacaine, in between the muscle layers of the abdomen (rectus sheath block) may help with pain relief during and after surgery. TEA uses a needle to insert a flexible plastic catheter into the thoracic spine to administer anesthetic and pain medication, such as bupivacaine and hydromorphone, to treat pain in the thoracic and upper abdominal areas during and after surgery. Epidurals have been successfully used to treat pain after surgery, however, it does have a risk of low blood pressure which may limit the use in the thoracic approach. Rectus sheath blocks with liposomal bupivacaine may be as effective as TEA in reducing pain in patients following a pancreatoduodenectomy.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To determine if rectus sheath blocks with liposomal bupivacaine provide non-inferior analgesia compared with thoracic epidural analgesia (TEA) for patients undergoing pancreatoduodenectomy. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP EPIDURAL (E): Prior to pancreatoduodenectomy, patients undergo thoracic epidural placement and receive bupivacaine and hydromorphone continuous infusion via epidural for up to 72 hours postoperatively. Patients also receive iopamidol via epidural and undergo x-ray imaging on study. GROUP RECTUS SHEATH (RS): Prior to pancreatoduodenectomy, patients undergo ultrasound and receive bupivacaine and liposomal bupivacaine injection into the rectus sheath. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06411795
Study type Interventional
Source Masonic Cancer Center, University of Minnesota
Contact
Status Recruiting
Phase Phase 2
Start date November 10, 2023
Completion date January 1, 2026

See also
  Status Clinical Trial Phase
Completed NCT01354795 - Prospective Study Comparing Methods of Obtainment of Specimen After EUS-FNA in Patients With Peri-pancreatic Mass N/A
Completed NCT00958841 - Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Phase 2
Terminated NCT00249301 - A Study of MLN8054 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT06122896 - Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals Early Phase 1
Terminated NCT02602067 - 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients Phase 1
Completed NCT03622229 - EUS-FNB for Solid Pancreatic Lesions: Side-fenestrated Vs Fork-tip Needle N/A
Recruiting NCT06400472 - A Study of LY4170156 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT02791503 - CROSSFIRE Trial: Comparing the Efficacy of Irreversible Electroporation With Radiotherapy N/A
Recruiting NCT05786716 - DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations Phase 2/Phase 3
Completed NCT03322592 - EUS-FNB With ROSE Vs. EUS-FNB Without ROSE N/A
Completed NCT05745415 - Cancer Stem Cell Specific Aptamer's Ability to Detect Blood Circulating Cancer Stem Cells and Its Role as a Predictor of Prognosis in Pancreatic Cancer
Recruiting NCT05083247 - Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma Phase 2
Completed NCT00436423 - A Phase Ⅱ Study of Gemcitabine Combination With TS-1 in Patient With Advanced or Recurred Pancreatic Cancer Phase 2
Completed NCT02900950 - Multicolour Versus Monocolour Specimens Inking After Pancreaticoduodenectomy for Periampullary Cancer N/A
Completed NCT00711191 - A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas Phase 1
Completed NCT00222898 - Cancer Detection in Pancreatic Cysts N/A
Completed NCT00034281 - Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 Phase 1
Completed NCT00005926 - Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas Phase 2
Recruiting NCT04164017 - Impact of Suction in the EUS-guided Fine Needle Biopsy of Solid Pancreatic Lesions N/A
Recruiting NCT05687123 - Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors Phase 1